

**PENNSYLVANIA DEPARTMENT OF HUMAN SERVICES**  
**Pharmacy & Therapeutics Committee Recommendations**  
**Tuesday, September 13, 2022**  
**12:30 p.m. to 4:00 p.m.**

**Committee Members Present:**

Ivonne Acrich, MD	Ad Hoc Child/Adolescent Psychiatrist
Dale Adair, MD, FAPA	Medical Director, Office of Mental Health & Substance Abuse Services
Christopher Antypas, PharmD	Community Pharmacist
Lawrence Appel, MD, SFHM	Medical Director, Office of Long-Term Living
Cheston Berlin Jr., MD	Pediatrician
Tony Byler, MD	PerformCare Psychiatrist
Terri Cathers, PharmD, Chair	OMAP Pharmacy Director
Sharon Connor, PharmD	Academic Pharmacist
Molly DiMatteo, DO	Family Practitioner
Oluwatoyin Fadeyibi, PharmD, MPH	Community Behavioral Health Pharmacist
Andrea Fox, MD	Internist
Donald Gerhart, RPh	Community Pharmacist
James Hancovsky, RPh, MBA	United Healthcare Pharmacy Director
Rosemary Keffer, MD	Ad Hoc Adult Psychiatrist
David Kelley, MD	OMAP Chief Medical Officer
Peter Kreckel, RPh	Community Pharmacist
Renee Licwinko, RPh	Gateway Health Plan Pharmacist
Andrew Maiorini, PharmD	Keystone/AmeriHealth Perform Rx Clinical Pharmacist
Meghan McNelly, PharmD	PA Health & Wellness Pharmacist
Michele Musheno, RPh, MS	Academic/Hospital Pharmacist
Geoffrey Neimark, MD	Community Care Behavioral Health Psychiatrist
Louis Parrott Jr., MD, PhD	Magellan Healthcare Psychiatrist
Ian Paul, MD, Vice Chair	Pediatrician
Adam Raphael Rom, MD	Family Practitioner
Amy Saracino, MD	Ad Hoc Adult Psychiatrist, OMHSAS
Kevin Szczecina, RPh	Geisinger Health Plan Pharmacist
Fallan Vaisberg, PharmD, RPh	Health Partners Plans Formulary Pharmacist
Andreas Wali, MD	Cardiologist
Lloyd Wertz	Consumer/Family Advocate
Lauren Zandier, PharmD	UPMC For You Pharmacist

**Committee Members Not Present:**

Mahmood Usman, MD, MMM	Beacon Health Options Psychiatrist
------------------------	------------------------------------

**PENNSYLVANIA DEPARTMENT OF HUMAN SERVICES**  
**Pharmacy & Therapeutics Committee Recommendations**  
**Wednesday, September 14, 2022**  
**9:00 a.m. to 1:30 p.m.**

**Committee Members Present:**

Ivonne Acrich, MD	Ad Hoc Child/Adolescent Psychiatrist
Dale Adair, MD, FAPA	Medical Director, Office of Mental Health & Substance Abuse Services
Christopher Antypas, PharmD	Community Pharmacist
Lawrence Appel, MD, SFHM	Medical Director, Office of Long-Term Living
Cheston Berlin Jr., MD	Pediatrician
Tony Byler, MD	PerformCare Psychiatrist
Terri Cathers, PharmD, Chair	OMAP Pharmacy Director
Sharon Connor, PharmD	Academic Pharmacist
Molly DiMatteo, DO	Family Practitioner
Oluwatoyin Fadeyibi, PharmD, MPH	Community Behavioral Health Pharmacist
Andrea Fox, MD	Internist
Donald Gerhart, RPh	Community Pharmacist
James Hancovsky, RPh, MBA	United Healthcare Pharmacy Director
Rosemary Keffer, MD	Ad Hoc Adult Psychiatrist
David Kelley, MD	OMAP Chief Medical Officer
Peter Kreckel, RPh	Community Pharmacist
Renee Licwinko, RPh	Gateway Health Plan Pharmacist
Andrew Maiorini, PharmD	Keystone/AmeriHealth Perform Rx Clinical Pharmacist
Meghan McNelly, PharmD	PA Health & Wellness Pharmacist
Michele Musheno, RPh, MS	Academic/Hospital Pharmacist
Geoffrey Neimark, MD	Community Care Behavioral Health Psychiatrist
Louis Parrott Jr., MD, PhD	Magellan Healthcare Psychiatrist
Ian Paul, MD, Vice Chair	Pediatrician
Adam Raphael Rom, MD	Family Practitioner
Amy Saracino, MD	Ad Hoc Adult Psychiatrist, OMHSAS
Kevin Szczecina, RPh	Geisinger Health Plan Pharmacist
Fallan Vaisberg, PharmD, RPh	Health Partners Plans Formulary Pharmacist
Andreas Wali, MD	Cardiologist
Lloyd Wertz	Consumer/Family Advocate
Lauren Zandier, PharmD	UPMC For You Pharmacist

**Committee Members Not Present:**

Mahmood Usman, MD, MMM	Beacon Health Options Psychiatrist
------------------------	------------------------------------

### **Public Testimony Presented to the Committee:**

Ahman Khan, PharmD (Horizon Therapeutics) – Krystexxa  
Alvin Kingcade (Bebashi Transition to Hope) – Symtuza  
Anna Loh, MD (Calliditas Therapeutics) – Tarpeyo  
Debbie Boldt-Houle (Tolmar Pharmaceuticals) - Fensolvi  
Diane Ammerman, PharmD (Genentech) – Ocrevus  
Elham “Elly” Fatehi, PharmD, MPH, BCPS (Janssen Pharmaceuticals, Inc.) – Symtuza  
Jack Bradley, PharmD (Supernus Pharmaceuticals) – Qelbree ER  
Jake Nichols (Renovo Health/US WorldMeds) – Lucemyra, Zimhi  
Jan Widerman, DO (Medically Assisted Recovery Services) – Vyvanse  
Jennifer Wilbanks (Sunovion) – Aptiom  
Jim Dowdle (United Therapeutics Corporation) – Tyvaso DPI  
John Meehan, PharmD, MPBA (Novartis Pharmaceuticals) – Kesimpta, Leqvio  
Maitrev Patel (Corium) – Azstarys  
Margaret Martin, PharmD, BCPS (Intra-Cellular Therapies, Inc.) – Caplyta  
Matthew Clark, MS (UCB) – Fintepla  
Michael Boskello, RPh (Alkermes, Inc.) – Lybalvi  
Niki Hwang (Bristol Myers Squibb) – Zeposia  
Olawemimo “Mimo” Odebiyi, PharmD (Teva Pharmaceuticals) – Ajoyv, ProAir Digihaler  
Punit Patel (Abbvie) – Oriahnn, Rinvoq ER, Skyrizi, Ubrelyv, Vraylar  
Rob Accetta (Rivercare Consulting LLC) – Norliqva  
Rod Scott (Tolmar Pharmaceuticals) – Fensolvi  
Ryan Gardner, PhD, BCMAS (Merz Therapeutics) – Xeomin  
Ryan Gregg, PhD (Ironshore Pharmaceuticals) – Jornay PM  
Vadim Garazov (GSK) – Nucala  
Vince Florio (UCB) – Briviact

### **Written Testimony Received by the Committee:**

Alan Kanouff, DO, FCCP (Altoona Lung Specialists) – Tezspire  
Alkermes, Inc. – Lybalvi  
Amgen – Aimovig, Avsola, Enbrel, Evenity, Lumakras, Neulasta Onpro, Otezla, Prolia, Repatha, Tezspire  
AnnMarie WolfSchatz, MD (Central Behavioral Health) – Vraylar  
AstraZeneca – Fasenra  
Aviva Rosenberg (Gaucher Community Alliance) – Enzyme Replacements, Gaucher Disease  
Biohaven Pharmaceuticals – Nurtec ODT  
Bristol Myers Squibb – Zeposia  
Britney Scolieri, DNP, PMHNP-BC (Summit Psychological Services) – Vraylar  
Calliditas Therapeutics – Tarpeyo  
Christine Rauscher, MD (Allegheny Health Network) – Tezspire  
Christopher Templin – Antihemophilia Agents  
David Kann, MD (Geisinger Health System, WellSpan Hospital) – Leqvio  
Deena Masciocchi, CRNP, PMHNP-BC (Lower Bucks Wellness) – Vraylar  
Eastern and Western Pennsylvania Bleeding Disorders Foundation – Antihemophilia Agents  
Frederico Xavier, MD, MS (The Hemophilia Center Western PA / UPMC Children’s Hospital of Pittsburgh) – Vonvendi  
Genentech – Ocrevus  
GlaxoSmithKline – Nucala

Horizon Therapeutics – Krystexxa  
 Intra-Cellular Therapies, Inc. – Caplyta  
 Janssen Pharmaceuticals, Inc. – Invega Hafyera, Opsumit, Symtuza, Upravi  
 JoMarie Peters, MSN, RN, PMHNP-NC (Human Services, Inc.) – Vraylar  
 Kristen Feldman, MD, FACOG (Afaxys) – Annovera  
 Luna Chen, DO (Elizabeth Township Family Medicine) – Obesity Treatment Agents  
 Margaret Ragni, MD, MPH (Hemophilia Center of Western Pennsylvania) – Vonvendi  
 Matthew Berger, MD, PC (Offices of Psychiatry & Counseling Services) – Lybalvi  
 Merz Therapeutics – Xeomin  
 Myovant Sciences – Myfembree  
 Neurelis, Inc. – Valtoco  
 Novartis Pharmaceuticals – Cosentyx, Kesimpta, Leqvio  
 Novo Nordisk Inc. – Norditropin Flexpro, Rebinyn, Wegovy  
 Paul Tayoun, DO (Hazleton Urgent Care) – Repatha  
 Pennsylvania Obesity Advocacy Group – Obesity Treatment Agents  
 Suhag Patel, PA-C (UPMC Neurological Institute) – Nurtec ODT  
 Supernus Pharmaceuticals – Qelbree ER  
 Takeda Pharmaceuticals – Advate, Adynovate, Entyvio, Hemofil M, Livtency, Recombinate, Trintellix, Vonvendi, Vpriv, Vyvanse  
 TherapeuticsMD – Annovera  
 US WorldMeds – Lucemyra, Zimhi  
 William Dozier, MBA (D2 Solutions) – Norliqva  
 Vicki March, MD, FACP (Solano & Kokales Internal Medicine Center) – Obesity Treatment Agents  
 Vitaliy Koss, MD, FAHS (Lehigh Valley Health Network) – Nurtec ODT

<b>Welcome and Introduction</b>	Dr. Terri Cathers welcomed the Committee and the members introduced themselves.
<b>Approval of September 2021 Minutes</b>	The Committee unanimously approved the minutes from the September 2021 meeting without revision.
<b>Drug Class Reviews, Public Testimony, Discussion, and Voting</b>	<p>The below attachment includes the P&amp;T Committee’s recommendations for preferred and non-preferred statuses for the drugs included on the Statewide Preferred Drug List (PDL) and the addition of Alcohol Use Disorder Agents and Obesity Treatment Agents to the PDL. Changes are highlighted in green.</p> <div data-bbox="590 1146 653 1211" data-label="Image"> </div> <p data-bbox="520 1219 730 1268">Post P&amp;T SW PDL 2023 with highlight:</p> <p data-bbox="520 1308 1108 1341"><b>Significant points of discussion by drug class:</b></p> <p data-bbox="520 1373 1934 1481"><b>Antipsychotics</b> – The Committee discussed the proposed revisions to the prior authorization guidelines and recommended minor clarifications. The Committee discussed the prior authorization process for beneficiaries being discharged from inpatient settings. Pharmacists on the Committee confirmed the availability of temporary supplies at the point-of-sale for drugs that require prior authorization to ensure beneficiaries do not leave the pharmacy without</p>

medication. The Committee ultimately approved the proposed revisions to the prior authorization guidelines with the clarifications discussed (one opposed, zero abstained).

**Hepatitis C Agents** – The Committee revisited the discussion from the 2021 P&T Committee meetings regarding removal of the requirement for prior authorization of preferred direct-acting antiviral Hepatitis C Agents. The Committee discussed strategies utilized in other states and the potential impact to the Pennsylvania Medical Assistance program and its beneficiaries. A suggestion was made to review data related to the prior authorization process at the next Department of Human Services (DHS) DUR Board meeting. The Committee agreed to a more in-depth discussion at the DHS DUR Board meeting. The Committee ultimately approved the proposed revisions to the prior authorization guidelines (zero opposed, six abstained).

**Obesity Treatment Agents** – The Committee discussed the addition of this class of drugs to Medical Assistance coverage as well as the Statewide PDL. Dr. Cathers reported that state regulation revisions are in process and coverage of these medications will begin January 2023. Dr. Verlyn Warrington, an obesity medicine specialist with the Guthrie Weight Loss Center in Sayre, PA, participated in the Committee's discussion. Dr. Warrington had no conflicts of interest to disclose. She addressed multiple questions and concerns raised by the Committee regarding Obesity Treatment Agents, treatment of obesity, and obesity-related comorbidities. The Committee also discussed use of amphetamine products in this class for the treatment of beneficiaries with psychiatric comorbidities. Dr. Warrington explained how she approaches these scenarios in her practice. The addition of this class to the Statewide PDL and recommendations for preferred and non-preferred statuses of the drugs in this class were approved by the Committee (zero opposed, one abstained). The corresponding prior authorization guidelines were also approved (three opposed, one abstained).

Prior authorization guidelines reviewed and approved by the P&T Committee are listed below. These guidelines are available on the Medical Assistance Advisory Committee (MAAC) listserv for the September 22, 2022, meeting for public comment:

- Acne Agents, Oral
- Alcohol Use Disorder Agents
- Antianginal Agents
- Antibiotics, GI and Related Agents
- Antihemophilia Agents
- Antipsoriatics, Topical
- Antipsychotics
- Antivirals, CMV
- Bile Salts
- Cytokine and CAM Antagonists
- Dupixent
- GI Motility, Chronic Agents
- Glucocorticoids, Inhaled
- Glucocorticoids, Oral
- Hepatitis C Agents
- Hypoglycemics, Incretin Mimetics-Enhancers
- Hypoglycemics, Insulins and Related Agents
- Hypoglycemics, SGLT2 Inhibitors
- Hypoglycemics, TZDs
- Immunomodulators, Atopic Dermatitis

	<ul style="list-style-type: none"><li>• Lipotropics, Other</li><li>• Monoclonal Antibodies (MABs) – Anti-IL, Anti-IgE, Anti-TSLP</li><li>• NSAIDs</li><li>• Obesity Treatment Agents</li><li>• Pituitary Suppressive Agents, LHRH</li><li>• Platelet Aggregation Inhibitors</li></ul>
<b>Meeting Adjourned</b>	Dr. Cathers thanked the Committee for their participation and adjourned the meeting at 1:30pm.